CGCarles García-Cervera

Carles García-Cervera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carles García-Cervera has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Implementing an Antimicrobial Stewardship Program for Optimizing Antibiotic Treatment in Gram-negative Bacilli Bacteremia

    by Carles García-Cervera, Francisco Mariano Jover-Díaz, Elisabet Delgado-Sánchez, Coral Martin-González, Rosa Provencio-Arranz, Ana Infante-Urrios, Cristina Dólera-Moreno, Pedro Esteve-Atiénzar, Teresa Martínez Lazcano, Jorge Peris-García, et al.

    García-Cervera C, et al. Infect Chemother. 2024 Jul;56:e30. https://doi.org/10.3947/ic.2024.0026


  • Report on the first two confirmed autochthonous cases of West Nile virus encephalitis in Catalonia, Spain

    by Carles García-Cervera, Simona Mihaela Iftimie, Miguel J. Martínez, Ana Vázquez González, Sandra Parra-Pérez, Laia Revuelta-López-Cordón, Joan Gil-Toral, Rosa Mercè Vileu Vallverdu, Ana Martínez Mateo, Ana Felisa López-Azcona, et al.

    West Nile virus (WNV) is a mosquito-borne flavivirus that can cause Central Nervous System infection in humans. Previous autochthonous cases of WNV encephalitis have been described in Spain, but none in Catalonia. We report on the first two autochthonous cases of encephalitis in humans caused by the West Nile virus (WNV) diagnosed in Catalonia (northeastern region of Spain). An old married couple presented with clinical and biological signs compatible with viral encephalitis. Acute and convalescent serum samples showed IgM and IgG positivity for WNV. In addition, IgM was also detected in cerebrospinal fluid in the male patient. The serological results were later confirmed by microneutralization assays. WNV infection must be considered in patients presenting with meningoencephalitis with viral CSF characteristics when common pathogens are excluded.


  • Estimation of Admission D-dimer Cut-off Value to Predict Venous Thrombotic Events in Hospitalized COVID-19 Patients: Analysis of the SEMI-COVID-19 Registry

    by Carles Garcia-Cervera, Vicente Giner-Galvan, Philip Wikman-Jorgensen, Jaime Laureiro, Manuel Rubio-Rivas, Anthony Gurjian Arena, Francisco Arnalich-Fernandez, Jose Luis Beato Perez, Juan Antonio Vargas Nunez, Jesus Javier Gonzalez Igual, et al.

    Background Venous thrombotic events (VTE) are frequent in COVID-19, and elevated plasma D-dimer (pDd) and dyspnea are common in both entities. Objective To determine the admission pDd cut-off value associated with in-hospital VTE in patients with COVID-19. Methods Multicenter, retrospective study analyzing the at-admission pDd cut-off value to predict VTE and anticoagulation intensity along hospitalization due to COVID-19. Results Among 9386 patients, 2.2% had VTE: 1.6% pulmonary embolism (PE), 0.4% deep vein thrombosis (DVT), and 0.2% both. Those with VTE had a higher prevalence of tachypnea (42.9% vs. 31.1%; p = 0.0005), basal O2 saturation 9/L; p = 0.0013). A pDd cut-off of 1.1 μg/ml showed specificity 72%, sensitivity 49%, positive predictive value (PPV) 4%, and negative predictive value (NPV) 99% for in-hospital VTE. A cut-off value of 4.7 μg/ml showed specificity of 95%, sensitivity of 27%, PPV of 9%, and NPV of 98%. Overall mortality was proportional to pDd value, with the lowest incidence for each pDd category depending on anticoagulation intensity: 26.3% for those with pDd >1.0 μg/ml treated with prophylactic dose (p < 0.0001), 28.8% for pDd for patients with pDd >2.0 μg/ml treated with intermediate dose (p = 0.0001), and 31.3% for those with pDd >3.0 μg/ml and full anticoagulation (p = 0.0183). Conclusions In hospitalized patients with COVID-19, a pDd value greater than 3.0 μg/ml can be considered to screen VTE and to consider full-dose anticoagulation.